@visus13

Oncology. Radiotherapy. Science. Development.

 Pamplona, Spain
Joined August 2010
  • Tweets4.5K
  • Following140
  • Followers227
175Media
Ignacio Visus retweeted
Enrique Grande
@drenriquegrandeOct 19
⚡️ Phase 2 trial in RCC with inferior vena cava tumor thrombus: neoadjuvant stereotactic ablative radiotherapy (SAbR) followed by surgery (n=23). 1-year recurrence-free survival: 71.4% — above the 55.7% historical benchmark. Thrombus downstaging in 22%. A promising approach for one of the most challenging complications in kidney cancer. #KidneyCancer #RCC @JAMAOnc jamanetwork.com/journals/jam…
2
32
1
52
3,625
Ignacio Visus retweeted
Alison Tree 💙@alison_treeOct 18
Replying to @alison_tree @TylerSbrt @a_dalpra @VedangMurthy @nickva1 @Adham_Hijab
..we do know that patients getting SBRT with fiducials on a standard linac had more GU AEs recorded pubmed.ncbi.nlm.nih.gov/4113…
3
3
9
534
🚨 Radioligand therapy before SBRT in oligorecurrent #prostatecancer 🚨 @EuropeanUrology - LUNAR trial 👥 n=92 orHSPC, 1-5 PSMA PET-detected lesions 📊 RCT phase 2 LUNAR, 2 cycles neoadjuvant 177Lu-PNT2002 then SBRT vs SBRT alone ⏱️ Median f/u 31.9 mo ✅ PFS 17.6 vs 7.4 mo, HR 0.38 (0.23-0.61), p<0.001 ✅ ADT-free survival HR 0.57 (0.34-0.95), p=0.03. NED at 24 mo 33% vs 12%, p=0.02 ✅ Exploratory: polymets-PFS HR 0.28, Castration-resistant-FS HR 0.13, CT-PFS HR 0.46 ⚠️ Secondary/Exploratory endpoints, wide CIs, small n. PSMA PET-defined events carry lead-time bias 🎯 Adding 177Lu before metastasis-directed SBRT may delay castration resistance and polymetastatic spread 🔗 doi.org/10.1016/j.eururo.202… @AmarUKishan @JeremieCalais @UCLAUrology @PCF_Science @UrologyTimes @urotoday @UroOnc
18
33
2,040
Ignacio Visus retweeted
PDBrown
@PDBrownOncOct 5
Placebo Controlled Randomized Trial: Memantine given w/Brain RT Improved Cognitive Outcomes & QOL 1/3 sciencedirect.com/science/ar…
3
28
1
65
3,574
Ignacio Visus retweeted
Nicholas van As@nickva1Sep 29
An honour to present the efficacy results of #PACE_A in the plenary and sexual function in the LBA at #ASTRO26 Take home message-give patients the data, let them make an informed choice
4
40
1
101
4,516
Ignacio Visus retweeted
Dr Najeed Aadil@daakhsaabSep 28
#ASTRO26: In PSMA-PET+ oligometastatic prostate cancer, adding SBRT to iADT showed: 📉 3-yr biochemical progression: 21% vs 60% (p=0.004) ⏱️ Time to progression: NR vs 27 mo 🔄 ADT re-initiation: 18% vs 41% (p=0.06) 📊 No significant QoL difference Promising signal for MDT!
🤖 Made with AI
1
26
47
2,531
#BladderCancer #TMT #ASTRO26 @ASTRO_org Guidelines by @drjefstathiou and team Key message Radiotherapy is a critical component of bladder cancer care. For selected patients with MIBC (cT2–4aN0M0), trimodality therapy is a guideline-supported alternative to radical cystectomy — combining maximal TURBT, concurrent radiosensitization and RT. 🎯 Bladder preservation is not a compromise. It is an evidence-based treatment strategy.
1
3
4
354
Ignacio Visus retweeted
Rashid K. Sayyid
@RKSayyidSep 28
GETUG P05: Ph 3 RCT of 46 Gy EBRT + LDR/HDR brachy boost vs dose-escalated 80 Gy EBRT in IR PCa, no ADT (n=288) 🔹5-yr bPFS: 88% vs 88.2% (p=0.90) 🔹No bPFS benefit in iether GG2 or 3 pts 🔹5-yr OS: 96% vs 92.7% (p=0.30) 🔹Acute GI toxicity lower w/ brachy: 30% vs 41% (p=0.03) 🔹Late GU toxicity higher w/ brachy: 82% vs 64% (p<0.01); G2: 34% vs 18%; G3 remained low: 3% vs 1% 🔑 Brachy boost did not improve biochemical control or OS but increased late urinary morbidity → modern dose-escalated EBRT remains the standard non-invasive option for IR PCa @urotoday #ASTRO26
10
16
710
Dr. Paul Brown: “It’s time to say thanks to PCI for its service.” #ASTRO26 @PDBrownOnc
7
19
1,043
Clinical trials session packed for some amazing trial data including long term clinical and functional outcomes for LDRT for knee osteoarthritis. Great work coordinating the publication of this data @KoneruMd ! #ASTRO2026
8
37
1,595
Ignacio Visus retweeted
Drew Moghanaki
@DrewMoghanakiSep 27
Controversial statement by @SJFrankMD, informed by the ProtecT study results, for those who still think prostatectomy is the better treatment. #ASTRO26
12
25
8
134
79,015
Imagine if we compared #brachy boost to SBRT?!? Will never get those data for FIR patients. @CDNCancerTrials PR24 is comparing brachy vs SBRT boost for UIR/HR/VHR prostate ca pts. Just passed 300/710 accruals!
Daniel E Spratt
@DrSpratticusSep 27
I’ve been saying this for years… Now we have randomized data. GETUG P05: brachytherapy boost vs dose-escalated EBRT in intermediate-risk prostate cancer. Oncologic outcomes similar but far more toxicity with brachy. #ASTRO26 #ProstateCancer @ASTRO_org @NehaVapiwala @AmarUKishan @DrAndrewLoblaw @seanmmcbride @HimanshuNagarMD @TylerSbrt @seanmmcbride @alison_tree @Soum_Roy_RadOnc @NicholasZaorsky @angela_jia_
1
5
32
2,997
The Varian Users Meeting was one of the highlights of the day. I mean look at this awesome holographic reveal of the new Accela unit! Multi lesion targeting @ 10 Gy each in under 30s. Full imaging to delivery workflows in under 90s. The future is really here! #ASTRO2026
1
11
1
63
10,050
Ignacio Visus retweeted
PDBrown
@PDBrownOncSep 26
🚨🚨Randomized Trial #ASTRO26 Small Cell Lung Cancer Brain Met fractionated SRS vs HA-WBRT 🚨 • No diff time to cognitive failure, neurologic death • SRS ↑↑ OS • ↑↑ AEs HA-WBRT • SRS standard of care SCLC brain met
5
84
9
188
18,104
Ignacio Visus retweeted
Rohit Malde@roxboxfixSep 20
OPEN trial Can an open-face thermoplastic mask, when combined with SGRT, maintain H&N RT setup accuracy while improving patient experience ? prospective, randomized phase III, 1:1:1 trial conducted at two radiotherapy centres N=200 pts Landmark trial incorporating OPEN masks
11
1
17
1,593
Ignacio Visus retweeted
Rohit Malde@roxboxfixSep 17
2026 ASTRO Clinical Practice Guideline on Radiation Therapy for Bladder Cancer Bladder preservation is now a clearly endorsed curative option For select cT2–4aN0M0 MIBC, ASTRO recommends trimodality therapy (TMT) as an alternative to radical cystectomy
37
1
75
3,466
Ignacio Visus retweeted
PDBrown
@PDBrownOncSep 12
🚨🚨 Randomized Trial #WCLC26 Small Cell Lung Cancer MRI +/-PCI 🚨 • MRI alone superior cognitive outcome • CFFS benefit of MRI alone similar in LS and ES-SCLC • No diff OS • MRI surveillance standard of care for SCLC
8
66
5
146
20,270
Ignacio Visus retweeted
Drew Moghanaki
@DrewMoghanakiSep 12
In my opinion, this presentation at #WCLC26 immortalizes Dr. Chad Rusthoven in the radiation oncology archives and elevates him to the status of hero among SCLC patient advocates.
9
20
2
96
8,637
Ignacio Visus retweeted
Drew Moghanaki
@DrewMoghanakiSep 11
I thoroughly enjoyed reading this recently published article led by @TroyKleberMD. It pulls back the curtain on how the largest cancer center in the US selects and manages patients with stage III NSCLC with induction chemoimmunotherapy. The framing is excellent, the results are unbiased, and the discussion is full of excellent pearls. The results also include a nice analysis of different RT strategies delivered after chemoimmunotherapy, including RT alone (without concurrent chemotherapy). #WCLC26 pubmed.ncbi.nlm.nih.gov/4270…
3
25
3
56
5,604
Does treatment intensification really put men with prostate cancer at greater fracture risk? 🦴 sciencedirect.com/science/ar… Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform A secondary STAMPEDE analysis evaluated fracture-related hospitalisation (FRH) among 3,102 men with #ProstateCancer receiving standard therapy with or without abiraterone💊based intensification. ➡️ In metastatic disease, abiraterone significantly reduced 5-year FRH compared with standard care, both alone and with enzalutamide. ➡️No significant difference emerged in non-metastatic disease. ✅These findings challenge concerns that abiraterone-based intensification increases fracture risk, suggesting improved metastatic bone control may instead reduce clinically significant fractures. @GrayStruan , @JanetBrown980 , @mccloskey_e , @wmcross , @MaxParmarMRCUCL , @mattsydes , @Prof_Nick_James @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists
2
23
2
52
5,595
Load more